Wolf Popper LLP Continues Its Investigation on Behalf of Investors in Harmony Biosciences Holdings, Inc.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing to investigate potential securities fraud claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony") common stock
GlobeNewswireApr 25 07:00 ET
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30,
PR NewswireApr 16 08:05 ET
Piper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)
TipRanksApr 12 08:30 ET
Harmony Inks Licensing Deal for Sleep Disorder Therapy
Seeking AlphaApr 11 12:36 ET
Harmony Biosciences Holdings (HRMY) Gets a Sell From Goldman Sachs
TipRanksApr 11 10:45 ET
Harmony Biosciences Secures Rights to Narcolepsy Treatment
InvestingApr 11 10:20 ET
Express News | Harmony Biosciences Shares Are Trading Higher After the Company Announced Exclusive Licensing Agreement With Bioprojet for TPM-1116 for Treatment of Narcolepsy
Moomoo 24/7Apr 11 08:54 ET
Express News | Harmony Biosciences Holdings Inc - Harmony Will Pay a Royalty Rate in Mid-Teens on Sales of Product in Licensed Territories
Moomoo 24/7Apr 11 08:06 ET
Express News | Harmony Biosciences Holdings Inc - Harmony Is Obligated to Pay up to $127.5 Mln Upon Achievement of Development and Regulatory Milestones
Moomoo 24/7Apr 11 08:06 ET
Express News | Harmony Biosciences- Will Pay Bioprojet $25.5 Mln for Exclusive Right to Develop, Manufacture & Commercialize Tpm-1116 in U.s, Latin America
Moomoo 24/7Apr 11 08:06 ET
Express News | Harmony Biosciences Holdings-by Deal Co to Pay Bioprojet License Fee of $25.5 Mln to Develop, Manufacture and Commercialize Tpm-1116 in U.S. and Latam
Moomoo 24/7Apr 11 08:06 ET
Express News | Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist
Moomoo 24/7Apr 11 08:05 ET
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
TipRanksApr 9 06:30 ET
Express News | Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
Moomoo 24/7Apr 9 06:24 ET
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms
Harmony Biosciences (HRMY) said Wednesday it has started the global phase 3 registrational trial of pitolisant to treat excessive daytime sleepiness and behavioral symptoms in patients aged six years
MT NewswiresApr 3 11:05 ET
Harmony Biosciences Has Initiated Its Phase 3 TEMPO Study For Pitolisant For Excessive Daytime Sleepiness And Behavioral Symptoms In Patients Aged Six Years And Older With Prader-Willi Syndrome
Harmony Biosciences Has Initiated Its Phase 3 TEMPO Study For Pitolisant For Excessive Daytime Sleepiness And Behavioral Symptoms In Patients Aged Six Years And Older With Prader-Willi Syndrome
BenzingaApr 3 08:08 ET
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their rece
BenzingaMar 28 12:00 ET
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upco
PR NewswireMar 26 08:05 ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)
TipRanksMar 25 12:50 ET
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing
Jeffrey Dierks, CHIEF COMMERCIAL OFFICER, on March 15, 2024, sold 11,979 shares in Harmony Biosciences Holdings (HRMY) for $383,328. SEC Filing: https://www.sec.gov/Archives/edgar/data/1802665/0001415
MT NewswiresMar 19 08:56 ET
No Data
No Data